GO:0004946 bombesin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004946 (bombesin receptor activity) is a molecular function defined as combining with bombesin to initiate a change in cell activity, mediated by the bombesin receptor family including NMBR, GRPR, BB3 and BRS3.
• The bombesin receptor family comprises four G-protein-coupled receptors that are activated by bombesin-related peptides and regulate diverse cellular responses in normal and malignant tissues.
• Bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism, linking this GPCR activity directly to oncogenic signaling.
• Bombesin receptor subtype-3 (BRS3) is an orphan receptor and a possible new target in lung-cancer cells, with subtype-specific ligands developed to probe its pharmacology.
• The nonpeptide agonist MK-5046 functions as an allosteric agonist for BRS3, demonstrating that bombesin receptor activity can be modulated by synthetic small molecules.
• Bombesin receptor family activation is being explored for targeted therapy in CNS and neural tumors, and radiopharmaceutical therapy in prostate cancer tumor microenvironments.
Description
GO:0004946, bombesin receptor activity, is a molecular function defined by the Gene Ontology as combining with bombesin to initiate a change in cell activity. Bombesin is a tetradecapeptide originally isolated from amphibian skin, and its mammalian counterparts include gastrin-releasing peptide (GRP) and neuromedin B (NMB), which act through a family of G-protein-coupled receptors (GPCRs). The bombesin receptor family consists of four members: the neuromedin B receptor (NMBR/BB1), the gastrin-releasing peptide receptor (GRPR/BB2), the orphan bombesin receptor subtype-3 (BRS3/BB3), and the amphibian bombesin receptor subtype-4 (BB4). These receptors share structural homology but differ in ligand selectivity, tissue distribution, and downstream signaling, making them important subjects for pharmacological and cancer research. Researchers study bombesin receptor activity because it sits at the intersection of neuropeptide signaling, cancer biology, and targeted therapeutics. Activation of bombesin receptors has been shown to stimulate growth of lung cancer cells through HER3 with a MAPK-dependent mechanism, providing a direct link between this GPCR activity and oncogenic proliferation. BRS3, an orphan receptor within this family, has emerged as a possible new target in lung-cancer cells, and subtype-specific ligands have been developed to dissect its pharmacology. Beyond lung cancer, bombesin receptor family activation is being investigated in CNS and neural tumors, and radiopharmaceutical therapy approaches are being explored in prostate cancer tumor microenvironments. Understanding GO:0004946 therefore requires integrating receptor pharmacology, downstream signaling, and disease context. The availability of selective agonists and antagonists, including the nonpeptide allosteric agonist MK-5046 for BRS3, enables precise interrogation of bombesin receptor activity in cellular and animal models. This article reviews the definition, mechanism, key genes, disease relevance, and research methods for bombesin receptor activity, with a focus on how CRISPR-based models can advance the field.
bombesin receptor activity At A Glance
| GO ID | GO:0004946 |
|---|---|
| GO term | bombesin receptor activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Combining with bombesin to initiate a change in cell activity. |
| Major function | Ligand-activated receptor signaling that converts bombesin or bombesin-related peptide binding into intracellular changes in cell activity. |
| Receptor family | Bombesin receptor family, including NMBR (BB1), GRPR (BB2), BRS3 (BB3), and BB4. |
| Endogenous ligands | Bombesin-related peptides such as gastrin-releasing peptide (GRP) and neuromedin B (NMB). |
| Disease relevance | Lung cancer growth signaling, CNS and neural tumors, and prostate cancer radiopharmaceutical therapy. |
| Pharmacology | Subtype-specific ligands and the nonpeptide allosteric agonist MK-5046 for BRS3. |
What Is GO:0004946?
In our own words, GO:0004946 (bombesin receptor activity) describes the molecular function of a receptor protein that binds bombesin (or bombesin-related peptides) and, upon binding, initiates a change in cell activity. This is a receptor activity term in the molecular_function ontology aspect, meaning it captures the ligand-binding and signal-initiation capability of bombesin receptors rather than a catalytic or structural role. The activity is typically mediated by G-protein-coupled receptors of the bombesin receptor family, which transduce extracellular bombesin-like peptide signals into intracellular responses.
Why Is bombesin receptor activity Important in Cell Biology?
Bombesin receptor activity is important because it links neuropeptide signaling to fundamental cellular responses and to human disease, particularly cancer. The bombesin receptor family is widely expressed in the nervous system and in various tumors, and activation of these receptors can stimulate proliferation and survival pathways. In lung cancer cells, bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism, identifying this activity as a potential therapeutic target. BRS3, an orphan receptor in this family, is a possible new target in lung-cancer cells, and the development of subtype-specific ligands has made it possible to selectively probe each receptor's function. Furthermore, bombesin receptor family activation is being explored for targeted therapy in CNS and neural tumors, and radiopharmaceutical therapy approaches in prostate cancer are being studied in the context of the tumor microenvironment. Understanding GO:0004946 therefore has direct implications for cancer biology, neuropharmacology, and the development of targeted therapeutics.
• Bombesin receptor activity mediates neuropeptide signaling in the central nervous system and peripheral tissues.
• Activation of bombesin receptors stimulates growth of lung cancer cells through HER3 and MAPK-dependent signaling.
• BRS3, an orphan bombesin receptor, is a possible new target in lung-cancer cells.
• Subtype-specific ligands enable selective pharmacological interrogation of each bombesin receptor.
• The nonpeptide agonist MK-5046 acts as an allosteric agonist for BRS3, expanding the toolbox for receptor modulation.
• Bombesin receptor family activation is being investigated for targeted therapy in CNS and neural tumors.
• Radiopharmaceutical therapy in prostate cancer tumor microenvironments may involve bombesin receptor-related biology.
• Bombesin receptor activity is a model GPCR signaling system for studying ligand selectivity and receptor activation.
• Dysregulation of bombesin receptor signaling is implicated in cancer proliferation and survival.
• CRISPR-based models can help determine the causal role of each bombesin receptor in disease.
Molecular Mechanism of bombesin receptor activity
Ligand binding and receptor activation
In simple terms: Bombesin-like peptides dock onto the receptor and switch it on.
Bombesin receptor activity begins with the binding of bombesin or bombesin-related peptides such as gastrin-releasing peptide (GRP) and neuromedin B (NMB) to the extracellular domains of the receptor. The bombesin receptor family includes NMBR, GRPR, BRS3, and BB4, which differ in their ligand selectivity and tissue distribution. Subtype-specific ligands have been identified through N-methyl scanning, truncation, and substitution studies, revealing the molecular basis for agonist selectivity at these receptors. For the orphan receptor BRS3, molecular studies have elucidated the basis for agonist selectivity and activation, showing that specific residues govern ligand recognition. Conformationally restricted bombesin analogs with enhanced selectivity for human BRS3 have also been developed, further defining the pharmacophore.
G-protein coupling and downstream signaling
In simple terms: Once switched on, the receptor triggers a relay of signals inside the cell.
Upon ligand binding, bombesin receptors couple to G-proteins and initiate intracellular signaling cascades that change cell activity. In lung cancer cells, bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism, demonstrating that this GPCR activity can transactivate receptor tyrosine kinases and engage mitogenic pathways. The nonpeptide agonist MK-5046 functions as an allosteric agonist for BRS3, indicating that receptor activation can be modulated at sites distinct from the orthosteric ligand-binding pocket. These signaling events convert extracellular bombesin-like peptide signals into changes in gene expression, proliferation, and survival.
Receptor subtype selectivity and pharmacology
In simple terms: Different receptors in the family respond to different ligands, and drugs can be designed to pick one.
The bombesin receptor family is characterized by subtype-specific pharmacology, which is critical for understanding GO:0004946 in different cellular contexts. N-methyl scanning, truncation, and substitution studies have identified bombesin receptor subtype-specific ligands, and putative reported selective ligands have been evaluated for their true selectivity. Conformationally restricted amino acid substitutions have yielded bombesin analogs with enhanced selectivity for the orphan receptor human BRS3. The molecular basis for agonist selectivity and activation of BRS3 has been dissected, providing a framework for designing subtype-selective compounds. The nonpeptide agonist MK-5046 further demonstrates that allosteric modulation of BRS3 is achievable.
Regulation of receptor activity
In simple terms: The cell can dial the receptor signal up or down.
Bombesin receptor activity is regulated at multiple levels, including ligand availability, receptor expression, and desensitization mechanisms. The presence of endogenous bombesin-related peptides such as GRP and NMB determines the extent of receptor activation in a given tissue. In cancer cells, bombesin receptor activation stimulates growth through HER3 and MAPK-dependent signaling, suggesting that downstream pathway components can modulate the overall response. The development of allosteric agonists such as MK-5046 for BRS3 indicates that receptor activity can be fine-tuned by ligands that bind outside the orthosteric site. Subtype-specific ligands also allow researchers to isolate the contribution of individual receptors to cellular responses.
Role in tumor microenvironment and targeted therapy
In simple terms: These receptors can be exploited to deliver therapy or to block tumor growth.
Bombesin receptor family activation has been reviewed as a possible target for novel targeted therapy in CNS and neural tumors. In lung cancer, BRS3 is considered a possible new target, and bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism. Radiopharmaceutical therapy in prostate cancer tumor microenvironments has been explored in silico with spatial transcriptomics, highlighting the potential of targeting bombesin receptor-related biology. These findings position GO:0004946 as a molecular function with direct translational relevance for cancer therapy.
Key Genes Involved in GO:0004946 bombesin receptor activity
The following genes and proteins are central to bombesin receptor activity, including the receptors themselves, their endogenous ligands, and key downstream signaling components.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRPR | Gastrin-releasing peptide receptor (BB2), a bombesin receptor family member that binds GRP and mediates bombesin receptor activity. | Target in lung cancer and other tumors; mediates growth signaling. |
| NMBR | Neuromedin B receptor (BB1), a bombesin receptor family member that binds neuromedin B. | Subtype-specific pharmacology and CNS signaling. |
| BRS3 | Bombesin receptor subtype-3 (BB3), an orphan receptor in the bombesin receptor family. | Possible new target in lung-cancer cells; allosteric modulation by MK-5046. |
| BB4 | Amphibian bombesin receptor subtype-4, a family member used in comparative pharmacology. | Model for understanding receptor subtype evolution and selectivity. |
| GRP | Gastrin-releasing peptide, an endogenous bombesin-related ligand that activates bombesin receptors. | Ligand for studying receptor activation and cancer growth. |
| NMB | Neuromedin B, an endogenous bombesin-related ligand that activates NMBR. | Ligand for subtype-selective activation studies. |
| HER3 | Receptor tyrosine kinase transactivated downstream of bombesin receptor activation in lung cancer cells. | Mediates MAPK-dependent growth stimulation. |
| MAPK1 | Mitogen-activated protein kinase 1, a downstream effector of bombesin receptor signaling. | Readout for MAPK-dependent growth. |
| MAPK3 | Mitogen-activated protein kinase 3, a downstream effector of bombesin receptor signaling. | Readout for MAPK-dependent growth. |
| GNAQ | G-protein alpha q subunit, a potential coupling partner for bombesin receptors. | Mediates downstream signaling from GPCR activation. |
| GNA11 | G-protein alpha 11 subunit, a potential coupling partner for bombesin receptors. | Mediates downstream signaling from GPCR activation. |
| GNAI1 | G-protein alpha i1 subunit, a potential coupling partner for bombesin receptors. | Mediates downstream signaling from GPCR activation. |
| SRC | Proto-oncogene tyrosine-protein kinase Src, a potential downstream effector of bombesin receptor signaling. | Links GPCR activation to oncogenic pathways. |
| EGFR | Epidermal growth factor receptor, a potential transactivation target of bombesin receptor signaling. | Receptor tyrosine kinase crosstalk in cancer. |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha, a potential downstream effector. | PI3K pathway activation in cancer. |
| AKT1 | AKT serine/threonine kinase 1, a potential downstream effector of bombesin receptor signaling. | Survival signaling readout. |
| MTOR | Mechanistic target of rapamycin kinase, a potential downstream effector of bombesin receptor signaling. | Growth and proliferation signaling. |
| FOS | FBJ murine osteosarcoma viral oncogene homolog, an immediate early gene responsive to GPCR signaling. | Transcriptional readout of receptor activation. |
How Is bombesin receptor activity Regulated?
Bombesin receptor activity is regulated by the availability of endogenous bombesin-related peptides such as gastrin-releasing peptide and neuromedin B, by receptor expression levels, and by downstream signaling feedback. Subtype-specific ligands and allosteric modulators such as MK-5046 for BRS3 provide pharmacological tools to regulate receptor activity experimentally. In cancer cells, bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism, indicating that the MAPK pathway is a key regulatory node downstream of these receptors. The tumor microenvironment may also influence bombesin receptor-related signaling, as suggested by in silico spatial transcriptomics studies in prostate cancer.
bombesin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRPR | Lung cancer growth signaling | Knockout and overexpression in lung cancer cell lines |
| BRS3 | Lung cancer, orphan receptor target | Knockout and point-mutation models to study ligand selectivity |
| NMBR | Neuropeptide signaling in cancer and CNS | Knockout models to dissect subtype-specific effects |
| HER3 | Lung cancer growth downstream of bombesin receptors | Knockout and knock-in of signaling mutants |
| MAPK1/MAPK3 | MAPK-dependent proliferation | Point-mutation models to block phosphorylation |
Lung cancer
Bombesin receptor activity is directly implicated in lung cancer biology. Activation of bombesin receptors stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism, providing a molecular link between this GPCR activity and oncogenic proliferation. BRS3, an orphan receptor in the bombesin receptor family, has been proposed as a possible new target in lung-cancer cells, and subtype-specific ligands have been developed to interrogate its function. These findings suggest that targeting bombesin receptor activity could be a therapeutic strategy in lung cancer.
CNS and neural tumors
Bombesin receptor family activation has been reviewed as a possible target for novel targeted therapy in CNS and neural tumors. The expression of bombesin receptors in neural tissues and tumors makes this molecular function relevant to neuro-oncology, and further research is needed to define which receptor subtypes are most important in specific tumor types.
Prostate cancer
Radiopharmaceutical therapy in prostate cancer tumor microenvironments has been explored in silico with spatial transcriptomics, and bombesin receptor-related biology may be part of the targeted therapy landscape. This suggests that bombesin receptor activity could be relevant to prostate cancer treatment strategies, although direct experimental validation is needed.
From bombesin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GRPR reduce lung cancer cell growth? | GRPR knockout cell lines |
| Does BRS3 activation require specific residues for ligand binding? | BRS3 point-mutation knock-in models |
| Can allosteric modulation of BRS3 be studied in cells? | BRS3 knock-in with tagged receptor and MK-5046 treatment |
| Does bombesin receptor activation transactivate HER3? | HER3 knockout or knockdown in lung cancer cells |
| Which receptor subtype mediates a specific cellular response? | Subtype-specific knockout and overexpression models |
| Can bombesin receptor activity be targeted in prostate cancer? | Prostate cancer cell models with receptor knockout |
How to Study the bombesin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Receptor affinity and subtype selectivity | Characterizing bombesin analogs and selective ligands |
| MAPK phosphorylation assay | Downstream MAPK pathway activation | Measuring bombesin receptor signaling in cancer cells |
| HER3 activation assay | Receptor tyrosine kinase transactivation | Linking bombesin receptor activity to growth signaling |
| Calcium mobilization assay | G-protein-coupled receptor activation | Functional screening of receptor agonists |
| Allosteric agonist profiling | Modulation of BRS3 activity by MK-5046 | Studying allosteric mechanisms |
| Structure-activity relationship studies | Ligand-receptor interaction determinants | Designing subtype-selective compounds |
| Spatial transcriptomics | Tumor microenvironment gene expression | Exploring radiopharmaceutical therapy in prostate cancer |
| CRISPR knockout screening | Causal role of bombesin receptor genes | Identifying which receptor mediates a phenotype |
Ligand-binding assays
Radioligand binding assays using bombesin analogs are used to measure receptor affinity and subtype selectivity, as demonstrated in studies identifying bombesin receptor subtype-specific ligands. These assays help determine whether a compound acts as an agonist or antagonist at each receptor subtype.
Signal transduction assays
Downstream signaling assays, such as MAPK phosphorylation and HER3 activation, are used to measure bombesin receptor activity in cells. These readouts connect receptor activation to changes in cell activity and are essential for functional characterization.
Pharmacological profiling with selective ligands
Subtype-specific ligands and allosteric agonists such as MK-5046 are used to profile receptor activity and to distinguish the contributions of NMBR, GRPR, and BRS3. N-methyl scanning and truncation studies provide structure-activity relationships for ligand design.
Transcriptomics and spatial profiling
In silico spatial transcriptomics has been used to explore the tumor microenvironment in prostate cancer in the context of radiopharmaceutical therapy, which may involve bombesin receptor-related biology. Transcriptomic profiling can also reveal expression patterns of bombesin receptors and their ligands in tumors.
How CRISPR Can Be Used to Study GO:0004946 bombesin receptor activity
Knockout
CRISPR knockout of bombesin receptor genes such as GRPR, NMBR, or BRS3 can determine whether a specific receptor is required for a cellular response, such as lung cancer cell growth. Knockout models are essential for establishing causality in bombesin receptor activity research.
Point Mutation
Point-mutation knock-in models can be used to test the role of specific residues in ligand binding and receptor activation, as suggested by molecular studies of BRS3 agonist selectivity. These models help dissect the structural basis of bombesin receptor activity.
Knock-in
Knock-in of tagged or reporter-tagged bombesin receptors allows visualization and tracking of receptor expression and localization in cells. This approach can be combined with pharmacological tools such as MK-5046 to study allosteric modulation.
Overexpression
Overexpression of bombesin receptors in cell lines can enhance signaling responses and is useful for studying receptor pharmacology and downstream pathways. Overexpression models complement knockout studies by providing gain-of-function readouts.
How EDITGENE Supports bombesin receptor activity Research
Researchers studying bombesin receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific cellular or disease phenotype. CRISPR-based models provide a precise way to test the roles of GRPR, NMBR, BRS3, and downstream signaling components in bombesin receptor biology.
Contact EDITGENE today to design your custom CRISPR model for bombesin receptor activity research.
Frequently Asked Questions About bombesin receptor activity
What is bombesin receptor activity?
Bombesin receptor activity (GO:0004946) is a molecular function defined as combining with bombesin to initiate a change in cell activity, mediated by the bombesin receptor family including NMBR, GRPR, BRS3, and BB4.
What genes are involved in bombesin receptor activity?
Key genes include GRPR, NMBR, BRS3, and BB4, as well as endogenous ligands such as GRP and NMB, and downstream effectors like HER3 and MAPK.
What is the function of bombesin receptor subtype-3 (BRS3)?
BRS3 is an orphan receptor in the bombesin receptor family and a possible new target in lung-cancer cells, with allosteric modulation by MK-5046.
How does bombesin receptor activation stimulate cancer growth?
In lung cancer cells, bombesin receptor activation stimulates growth through HER3 with a MAPK-dependent mechanism.
What are the endogenous ligands for bombesin receptors?
Endogenous bombesin-related peptides include gastrin-releasing peptide (GRP) and neuromedin B (NMB).
What diseases are associated with bombesin receptor activity?
Bombesin receptor activity is implicated in lung cancer, CNS and neural tumors, and prostate cancer tumor microenvironment biology.
How can I study bombesin receptor activity in the lab?
Common methods include radioligand binding assays, MAPK phosphorylation assays, HER3 activation assays, and CRISPR knockout models.
What is MK-5046?
MK-5046 is a nonpeptide agonist that functions as an allosteric agonist for bombesin receptor subtype-3 (BRS3).
Can CRISPR be used to study bombesin receptors?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can be used to dissect the roles of bombesin receptors and downstream signaling components.
What is the GO ID for bombesin receptor activity?
The GO ID for bombesin receptor activity is GO:0004946, classified under the molecular_function ontology aspect.
Conclusion
GO:0004946 (bombesin receptor activity) is a molecular function that connects bombesin-related neuropeptide signaling to changes in cell activity through the bombesin receptor family. Its relevance spans cancer biology, neuropharmacology, and targeted therapeutics, with lung cancer and CNS tumors being prominent disease contexts. The availability of subtype-specific ligands and allosteric modulators such as MK-5046 provides powerful tools for dissecting receptor pharmacology. CRISPR-based models, including knockout, point-mutation, knock-in, and overexpression cell lines, are essential for establishing causal roles of bombesin receptors and their downstream effectors in disease phenotypes. Continued research into bombesin receptor activity will likely yield new insights into GPCR signaling and novel therapeutic strategies for cancer and other diseases.
References
- 1. Moody TW et al.. 2021. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.. Front Endocrinol (Lausanne) 12:728088 PMID: 34539578
- 2. Ramos-Alvarez I et al.. 2022. The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.. J Pharmacol Exp Ther 382(2):66-78 PMID: 35644465
- 3. Moreno P et al.. 2018. A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.. Peptides 101:213-226 PMID: 29410320
- 4. Lee L et al.. 2020. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.. Biochim Biophys Acta Mol Cell Res 1867(4):118625 PMID: 31862538
- 5. Mantey SA et al.. 2006. Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands.. J Pharmacol Exp Ther 319(2):980-9 PMID: 16943256
- 6. Hong J et al.. 2024. Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.. Theranostics 14(18):7122-7139 PMID: 39629134
- 7. Gonzalez N et al.. 2008. Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.. J Pharmacol Exp Ther 324(2):463-74 PMID: 18006692
- 8. Mantey SA et al.. 2004. Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3.. J Pharmacol Exp Ther 310(3):1161-70 PMID: 15102928
